# CAPTAIN-1st (NCT03707509)

> Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

No report yet. It can be ordered.

- Drugs tested: camrelizumab
- Indication: first-line recurrent or metastatic nasopharyngeal carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03707509
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Conditions: Nasopharyngeal Carcinoma
- Interventions: Camrelizumab; Placebos; Gemcitabine; Cisplatin
- Enrollment: 263
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on CAPTAIN-1st so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=captain-1st-nct03707509